SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

10443	Companies
219247	Keywords
148701	Articles
115972	Press releases

Home
Companies
SANOFI-AVENTIS

BRIEF

published on 10/17/2025 at 13:05, 7 months 6 days ago

Sanofi faces negative EU opinion on Rezurock

Europe Sanofi CHMP Rezurock CGVHD
PRESS RELEASE

published on 10/17/2025 at 13:00, 7 months 6 days ago

Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi announces negative CHMP opinion on Rezurock for chronic graft-vs-host disease in the EU but plans to seek re-examination. Rezurock has shown efficacy in clinical studies

EU Sanofi CHMP Rezurock CGVHD
BRIEF

published on 10/08/2025 at 07:05, 7 months 15 days ago

AlphaMedixTM: Positive Phase 2 Results for the Treatment of GEP-NETs

Clinical Trial Phase 2 Innovative Therapy AlphaMedixTM TNE-GEP
BRIEF

published on 09/24/2025 at 07:10, 7 months 29 days ago

Sanofi invests $625 million to boost Sanofi Ventures

Innovation Digital Health Investment Sanofi Biotechnologies
BRIEF

published on 09/24/2025 at 07:05, 7 months 29 days ago

Sanofi Releases Q3 2025 Aide Mémoire

Investor Relations Sanofi Financial Modeling Results Announcement Q3 2025
PRESS RELEASE

published on 09/24/2025 at 07:05, 7 months 29 days ago

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits $625 million to Sanofi Ventures to boost biotech and digital health investments. Focus on immunology, rare diseases, neurology, vaccines

Digital Health Investment Biotech Ventures Sanofi
PRESS RELEASE

published on 09/24/2025 at 07:00, 7 months 29 days ago

Press release: Availability of the Q3 2025 Aide mémoire
Sanofi announces availability of Q3 2025 Aide mémoire for financial modeling purposes. Document covers non-comparable items, foreign currency impact, and share count

Investors Sanofi Financial Modeling Aide Mémoire Q3 2025
BRIEF

published on 09/23/2025 at 07:05, 8 months ago

Sanofi's SAR446268 Therapy Advances in the United States

Gene Therapy Sanofi SAR446268 FDA Admission Myotonic Dystrophy
PRESS RELEASE

published on 09/23/2025 at 07:00, 8 months ago

Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi's SAR446268 granted US fast track designation for non-congenital myotonic dystrophy type 1. AAV gene therapy aims to silence DMPK expression, addressing symptoms and filling unmet need

AAV Gene Therapy Sanofi Fast Track Designation SAR446268 Myotonic Dystrophy Type 1
BRIEF

published on 09/17/2025 at 07:05, 8 months 6 days ago

Sanofi's Brivekimig Shows Promise in Hidradenitis Suppurativa Treatment

Brivekimig Hidradenitis Suppurativa Phase 2a Study Nanobody Technology Immune-mediated Diseases

Accesswire

Published on 05/23/2026 at 19:45, 2 hours 9 minutes ago

Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 18 hours 39 minutes ago

UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 18 hours 54 minutes ago

Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 19 hours 29 minutes ago

Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 19 hours 29 minutes ago

Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec

View all ACCESSWIRE

EQS Group

Published on 05/23/2026 at 16:30, 5 hours 23 minutes ago

HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 5 hours 57 minutes ago

EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 23 hours 49 minutes ago

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 2 hours ago

Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 1 day 3 hours ago

Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring

Les Echos

Published on 05/22/2026 at 18:05, 1 day 3 hours ago

Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 9 hours ago

Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
Published on 05/22/2026 at 08:30, 1 day 13 hours ago

Eiffage is building four solar power plants for the NOOR Atlas programme in Morocco
Published on 05/21/2026 at 17:50, 2 days 4 hours ago

CDA - H1 results 2025 2026
Published on 05/21/2026 at 17:45, 2 days 4 hours ago

CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE